Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

NCT02866370 is registered in ClinicalTrials.gov with NHS Greater Glasgow and Clyde as lead sponsor.

NCT NCT02866370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02866370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
Lead sponsor
NHS Greater Glasgow and Clyde
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2015
Completion date
March 31, 2021
Enrollment
120 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial clear cell carcinoma, ovarian clear cell carcinoma